Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Takhzyro

    - PMLiVE

    BMS, Takeda and Astex join AI training consortium

    The initiative focuses on training AI models to aid in drug discovery and development

    - PMLiVE

    MHRA approves KalVista Pharmaceuticals’ Ekterly to treat hereditary angioedema attacks

    Ekterly is now the first and only oral on-demand treatment for HAE to be approved by the UK regulator

    - PMLiVE

    FDA approves CSL’s Andembry to prevent hereditary angioedema attacks

    The genetic disorder affects approximately one in 10,000 to one in 50,000 people worldwide

    - PMLiVE

    Takeda receives EC approval for Adcetris combination in Hodgkin lymphoma

    The decision marks the second approval for an Adcetris-based regimen for front-line Hodgkin lymphoma

    - PMLiVE

    Takeda’s Adzynma approved by MHRA for rare blood clotting disorder cTTP

    The enzyme replacement therapy is now the first treatment approved in the UK for this patient population

    - PMLiVE

    MHRA approves Bavarian Nordic’s chikungunya vaccine Vimkunya

    Approximately 620,000 cases of the mosquito-borne viral disease were reported worldwide in 2024

    - PMLiVE

    Takeda receives CHMP recommendation for Adcetris in Hodgkin lymphoma

    The EC will review the committee’s positive opinion as it makes a decision on Adcetris in this indication

    - PMLiVE

    Takeda receives NICE recommendation for Adcetris combination in Hodgkin lymphoma

    Around 800 people in the UK are diagnosed with late-stage disease every year

    - PMLiVE

    Takeda/Protagonist share positive phase 3 results for rusfertide in rare blood cancer

    Up to 160,000 people in the US are affected by polycythaemia vera

    EU flag

    EC approves CSL’s Andembry to prevent hereditary angioedema attacks

    Approximately one in every 50,000 people worldwide are affected by the rare genetic disorder

    - PMLiVE

    MHRA approves CSL’s Andembry to treat angioedema attacks in HAE patients

    The rare genetic condition occurs in approximately one in every 50,000 people in the UK

    - PMLiVE

    Takeda and EU Innovative Health Initiative launch Crohn’s disease prevention study

    Approximately three million people in Europe are affected by inflammatory bowel disease

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links